Peter Voorhees, MD

Articles by Peter Voorhees, MD

Consideration in Treatment Selection and Sequencing in R/R MM

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

October 11th 2024

The panel discusses how they approach treatment selection and sequencing for patients with relapsed/refractory multiple myeloma.

Clinical Scenario 2: A 70-Year-Old Male with R/R MM

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

October 11th 2024

Shaji Kumar, MD, presents the case of a 70-year-old patient with relapsed/refractory multiple myeloma who received CAR T-cell therapy.

Pooled Analysis from MagnetisMM Studies

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

October 4th 2024

Thomas G. Martin, MD, reviews findings from a pooled analysis from MagnetisMM that evaluated elranatamab in patients with relapsed/refractory MM who received prior BCMA-directed therapies.

Sequencing Options of Bispecifics in R/R MM

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

September 27th 2024

Focusing on treatment paradigms for patients with relapsed/refractory multiple myeloma, the expert panel discusses the role of BCMA-targeted bispecifics and how they might consider sequencing therapies.

Treatment Options in Late-line R/R MM Patients

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

September 20th 2024

Following the presentation of a case of a patient with multiple myeloma, the panel have a roundtable discussion on how to approach treatment.

Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

ByPeter Voorhees, MD,Shaji Kumar, MD, Mayo Clinic,Ariel Grajales-Cruz, MD,Thomas G. Martin, MD

September 20th 2024

A panel of myeloma specialists review the case of a 67-year-old patient with multiple myeloma (MM) who received a bispecific antibody.

A panel of 4 experts on multiple myeloma seated at a long table

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

Concluding their comprehensive discussion on treating patients with multiple myeloma, the expert panel discusses unmet needs and looks to the future of treatment.

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 18th 2023

The panel presents the case of a 68-year-old man with multiple myeloma and offers their initial impressions.

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

Shared insights on the patient profile of a 75-year-old woman with multiple myeloma with confirmed lytic disease.

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 11th 2023

The expert panel presents the patient case of a 70-year-old man with multiple myeloma and discusses treatment decisions.

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

An overview of the RedirecTT-1 study investigating teclistamab plus talquetamab in patients with relapsed/refractory multiple myeloma.

Talquetamab for Patients With Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

October 4th 2023

Continuing discussion on bispecific antibodies, attention turns to talquetamab and the MonumenTAL-1 clinical trial for patients with relapsed/refractory multiple myeloma.

Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 27th 2023

Specialists in the field of multiple myeloma discuss bispecific antibodies, with a focus on the MajesTEC-1 study on teclistamab.

MM: Influence of CAR T-Cell Therapy on Clinical Care

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 27th 2023

The panel discusses how the emergence of CAR T-cell therapy has changed clinical care for patients with multiple myeloma.

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A comprehensive overview of emerging data from the KarMMa-3 and CARTITUDE-4 studies on CAR T-cell therapy in relapsed/refractory multiple myeloma.

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 20th 2023

A panel of experts discuss treatment and CAR T-cell therapy options for patients with relapsed/refractory disease who have limited treatment choices.

Assessing Frailty in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Expert perspectives on assessing frailty for patients with multiple myeloma and its effect on treatment decisions.

Treatment Strategies for Patients With Transplant-Ineligible MM

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 13th 2023

Clinical insights on treatment options and strategies for patients with multiple myeloma who are not eligible for transplant.

Transplant and Treatment Decision-Making in Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 6th 2023

The expert panel discusses factors that influence referral to transplant as well as selecting maintenance and consolidation therapies for patients with multiple myeloma.

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

September 6th 2023

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Treatment Options for Patients With Newly Diagnosed Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

August 30th 2023

A detailed overview of therapeutic options for patients undergoing treatment for newly diagnosed multiple myeloma.

The Role of Transplant in Newly Diagnosed Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

August 30th 2023

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

December 15th 2022

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.

Bispecifics in Development for the Treatment of R/R MM

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

December 8th 2022

Dr Tuchman highlights exciting bispecific agents in investigation for the treatment of relapsed/refractory multiple myeloma.

Treatment Options for Patients with Relapsed Multiple Myeloma

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

December 8th 2022

Peter Voorhees, MD, starts a conversation on the best treatment options for patients with multiple myeloma after relapse.

Defining Frail Patients in Multiple Myeloma

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

December 1st 2022

Sascha Tuchman, MD, discusses how frail patients with multiple myeloma are defined in his clinical practice, and what assessment models he utilizes.

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

December 1st 2022

Dr Sascha Tuchman explains how he measures an adequate or successful frontline treatment response in patients with transplant-ineligible NDMM.

Data Updates in Transplant Ineligible NDMM

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

November 25th 2022

Dr Christina Gasparetto compares the results of the MAIA and SWOG0777 trials and discusses how the data has been practice-changing.

Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

November 25th 2022

Dr Varga and Dr Tuchman explain the factors for consideration when choosing an initial treatment regimen for patients with transplant-ineligible NDMM.

Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

ByPeter Voorhees, MD,Cristina Gasparetto, MD,Cindy Varga, MD,Sascha Tuchman, MD

November 17th 2022

Drs Tuchman and Gasparetto present two profiles of patients with transplant-ineligible NDMM.

Peter Voorhees, MD

Articles by Peter Voorhees, MD

Consideration in Treatment Selection and Sequencing in R/R MM

Clinical Scenario 2: A 70-Year-Old Male with R/R MM

Pooled Analysis from MagnetisMM Studies

Sequencing Options of Bispecifics in R/R MM

Treatment Options in Late-line R/R MM Patients

Clinical Scenario 1: A 67-Year-Old Man with Multiple Myeloma

Unmet Needs and Future Perspectives on Treating Patients With Multiple Myeloma

Patient Profile 3: A 68-Year-Old With Multiple Myeloma

Patient Profile 2: A 75-Year-Old With Multiple Myeloma With Lytic Disease

Patient Profile 1: A 70-Year-Old With Multiple Myeloma

RedirecTT-1: Teclistamab Plus Talquetamab in Relapsed/Refractory MM

Talquetamab for Patients With Relapsed/Refractory MM

Bispecific Antibodies: Teclistamab for Patients With Relapsed/Refractory MM

MM: Influence of CAR T-Cell Therapy on Clinical Care

CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma

Multiple Myeloma: Treating Patients Who Have Relapsed Multiple Times

Assessing Frailty in Multiple Myeloma

Treatment Strategies for Patients With Transplant-Ineligible MM

Transplant and Treatment Decision-Making in Multiple Myeloma

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

Treatment Options for Patients With Newly Diagnosed Multiple Myeloma

The Role of Transplant in Newly Diagnosed Multiple Myeloma

Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

Bispecifics in Development for the Treatment of R/R MM

Treatment Options for Patients with Relapsed Multiple Myeloma

Defining Frail Patients in Multiple Myeloma

Measuring Treatment Response and Duration of Treatment in Transplant-Ineligible MM

Data Updates in Transplant Ineligible NDMM

Selecting Frontline Treatment Regimens for Transplant-Ineligible MM

Patient Profiles: Transplant-Ineligible Newly-Diagnosed Multiple Myeloma

Trending on CancerNetwork

KEYNOTE-B49 Points to a PD-L1-Defined Subset Benefiting From Immunotherapy in Breast Cancer

Closing the Gaps in Precision Oncology for Breast Cancer

Navigating PD-L1–Low Gastroesophageal Cancer Treatment and Payer Challenges

Managing Patients With No Pathologic Response After Durvalumab Plus FLOT

Blood mRNA Model Predicts Castration Resistance in Metastatic Prostate Cancer